Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RHO Phyto Deep Tissue Gels is a cannabinoid-based topical formulation developed by Avicanna Inc. The product contains a combination of cannabidiol (CBD), menthol, clove oil, and natural polyphenols, delivered via an advanced emulsion technology designed for deep tissue penetration and absorption. It is primarily used for the relief of pain and inflammation, particularly in conditions like osteoarthritis. Launched in Canada in 2021 as a medical cannabis product, it is also being investigated in clinical studies for its impact on sleep disturbances, anxiety, and depression. The developer aims to eventually register the formulation as an over-the-counter (OTC) drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RHO Phyto Deep Tissue Gels.